Clinical Trial Update: Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer [NA]

View source ↗

Summary

A completed breast cancer trial evaluating adjuvant doxorubicin/cyclophosphamide and paclitaxel with sorafenib, with results posted on 2013-01-25.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Adriamycin (doxorubicin)
• Cytoxan (cyclophosphamide)
• Nexavar (Sorafenib)
• Taxol (paclitaxel)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Breast Cancer | NA | Status: COMPLETED | Results posted: 2013-01-25